Industrial Pharmacy
The Industrial Pharmacy Section of the 2007 FIP Congress focuses on the crucial need for pharmacists to assume responsibility for the delivery of safe and effective medicine along every point of the medicines supply chain. Pharmacists should insist on involvement in all processes, from manufacture to delivery. Focus should be on the areas in which pharmacists are the primary healthcare provider, namely at the point of dispensing, to ensure accurate and ethical information is conveyed to the patient. The pharmacist is the last point of defence against misinformation and counterfeit medical products, and should be well equipped and willing to take appropriate measures to protect patients.
All stakeholders in the drug distribution channel - from the pharmaceutical industry to the pharmacy counter- have a joint responsibility to ensure quality throughout the life cycle of a drug. Pharmacists need to be aware of risks pertaining to improper information and dispensing and the threat such practices pose to patient safety. Pharmacists must also understand the financial and rational consequences to both patients and industry of poor adherence and wrong usage of medicines. Topics go beyond manufacture and distribution to include a session on pharmaceuticals and the environment, examining risk factors of environmental pollution caused by medicines. Some of the most recent advances in nanotechnology will also be shared to foster an appreciation of the challenges of developing medicinal nanotechnology and its application in an industrial setting. FIP is also pleased to welcome industrial pharmacists and scientists to give short oral contributions on manufacturing/GMP and drug delivery techniques or processes.
Limiting the spread of substances that do not occur naturally in the environment is central to its protection. Environmental activities must, therefore, concentrate on investigating and revealing their properties and on ensuring that they have minimal impact on the environment and that their use and disposal take place in a manner that, as far as possible, prevents them from spreading.
Pharmaceuticals contain chemical substances and are, therefore, an important area to take into account in the endeavour to achieve a non-toxic environment. Having knowledge and the ability to manipulate environmental effects are essential when drugs are developed, and contributes to safe and proper utilisation. Environmental issues should never become a reason to refrain from pharmacological treatment choices.
» full programme
All stakeholders in the drug distribution channel – from the pharmaceutical industry to the pharmacy – have a joint responsibility throughout the life cycle of a drug to ensure effectiveness and the best therapeutic outcome of pharmaceutical products. This demands high quality in the product and in the information available to healthcare professionals and patients in order to ensure the best use of the drug. The ultimate goal is safe and correct use of pharmaceuticals for the sake of patient safety and obtaining the best therapeutic outcome.
» full programme
The following topics will be discussed in this session:
- Implementation of GMP
- GMP practice in
Europe
- GCP practice in multi-center studies
-
GCP practice in
USA
» full programme
At the conclusion of this session, participants will be able to appreciate the challenges of the development of medicinal nanotechnology and its applications in an industrial setting.
» full programme
Industrial pharmacists and scientists will give short oral contributions on a challenging problem related to manufacturing or GMP. Each presenter will deliver his/her contribution in an interactive way, discussing the topic directly with the audience and/or with members of the expert panel.
» full programme
Industrial pharmacists and scientists will give short oral contributions on a challenging problem related to drug delivery. Each presenter will deliver his/her contribution in an interactive way, discussing the topic directly with the audience and/or with members of the expert panel.
» full programme
No matter where in the world community pharmacists are practicing, issues such as pharmacist prescribing (
USA
: Collaborative practice), deregulation of the pharmacy sector, leadership and succession, and the role of the pharmacist are being discussed. It is crucial to maintain an open debate within the profession, encompassing policy makers and practicing pharmacists as well as future professionals. » full programme
* These sessions are accredited by ACPE for continuing education units. For more information on accreditation, please email congress@fip.org
I would like to register for the FIP Congress in Beijing.
|